(Q39907871)

15 September 2017

1 reference

title

Antiparkinsonian drugs: pharmacological and therapeutic aspects (English)

1 reference

15 September 2017

1

D B Calne

1 reference

15 September 2017

J L Reid

2

1 reference

PubMed ID

4405376

15 September 2017

language of work or name

1 reference

1 January 1972

1 reference

15 September 2017

1 reference

15 September 2017

4

1 reference

15 September 2017

1

1 reference

15 September 2017

49-74

1 reference

Stimulation of Human-Growth-Hormone Secretion by L-Dopa

15 September 2017

1 reference

12 December 2020

Parkinsonism: onset, progression, and mortality

1 reference

12 December 2020

Striatal amines, experimental tremor and the effect of harmaline in the monkey.

1 reference

12 December 2020

The role of biogenic amines in the extra-pyramidal system

1 reference

12 December 2020

Dopamine (3-hydroxytyramine) and brain function

1 reference

12 December 2020

Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays

1 reference

12 December 2020

Corticosteroid and growth hormone secretion in patients treated with L-dopa.

1 reference

12 December 2020

The distribution of acetylcholinesterase and butyryl-cholinesterase in the human brain.

1 reference

12 December 2020

Theoretical implications of the use of L-dopa in parkinsonism. A review

1 reference

12 December 2020

L-Dihydroxyphenylalanine: Effect on S -Adenosylmethionine in Brain

1 reference

12 December 2020

The metabolism of orally administered l-DOPA in Parkinsonism

1 reference

12 December 2020

Cholinergic enzyme systems in Parkinson's disease.

1 reference

12 December 2020

Oxprenolol in Parkinson's disease.

1 reference

12 December 2020

Amantadine in the Treatment of Parkinson's Disease

1 reference

12 December 2020

Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

1 reference

12 December 2020

Amantadine in parkinsonism

1 reference

12 December 2020

Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.

1 reference

12 December 2020

Mental symptoms in parkinsonism following benzhexol hydrochloride therapy.

1 reference

12 December 2020

Controlled trial of amantadine hydrochloride in Parkinson's disease.

1 reference

12 December 2020

INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM

1 reference

12 December 2020

In vitro studies on central and peripheral monoamine neurons at the ultrastructural level

1 reference

12 December 2020

3-O-Methyldopa, a New Precursor of Dopamine

1 reference

12 December 2020

The release of dopamine from the putamen

1 reference

12 December 2020

Long-term side-effects of levodopa.

1 reference

12 December 2020

Apomorphine in Parkinson's disease

1 reference

12 December 2020

Imipramine hydrochloride (Tofranil) in Parkinsonism. A preliminary report.

1 reference

12 December 2020

Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism

1 reference

12 December 2020

False neurotransmitters and hepatic failure.

1 reference

12 December 2020

Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients

1 reference

12 December 2020

Metabolic Studies and Clinical Observations During L-Dopa Treatment of Parkinson's Disease

1 reference

12 December 2020

Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas.

1 reference

12 December 2020

Neurological disease in an English city.

1 reference

12 December 2020

Levodopa, Parkinson's Disease, and Hypotension

1 reference

12 December 2020

L-dopa treatment failure: explanation and correction

1 reference

12 December 2020

Possible role of dopamine as transmitter to promote discharge of LH-releasing factor.

1 reference

12 December 2020

Cholinergic mechanisms in the caudate nucleus

1 reference

12 December 2020

[The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis]

1 reference

12 December 2020

Clinical trial with a beta-receptor antagonist (propranolol) in parkinsonism

1 reference

12 December 2020

THE RELEASE OF ACETYLCHOLINE AND OF 3-HYDROXYTYRAMINE FROM THE CAUDATE NUCLEUS.

1 reference

12 December 2020

Non-enzymatic decarboxylation of dihydroxyphenylalanine

1 reference

12 December 2020

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

1 reference

12 December 2020

On the mode of action of amantadine.

1 reference

12 December 2020

1 reference

12 December 2020

Dopamine, amino acids and caudate unitary responses to nigral stimulation.

1 reference

12 December 2020

Tranylcypromine and the extrapyramidal syndromes.

1 reference

12 December 2020

Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa

1 reference

12 December 2020

Interaction of DOPA Decarboxylase Inhibitors with the Effect of α-Methyldopa on Blood Pressure and Tissue Monoamines in Rats1

1 reference

12 December 2020

A survey of drug-induced extrapyramidal reactions

1 reference

12 December 2020

[On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6]

1 reference

12 December 2020

Potentiation of the l-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors

1 reference

12 December 2020

Levodopa in hepatic coma.

1 reference

12 December 2020

L-dopa therapy in Parkinson's disease: a critical review of nine years' experience

1 reference

12 December 2020

Absorption, distribution and excretion of amantadine hydrochloride

1 reference

12 December 2020

Choline acetylase in the central nervous system of man and some other mammals

1 reference

12 December 2020

Histochemical studies on the effect of (+)-amphetamine, drugs of the imipramine group and tryptamine on central catecholamine and 5-hydroxytryptamine neurons after intraventricular injection of catecholamines and 5-hydroxytryptamine

1 reference

12 December 2020

Effect of L-DOPA on brain monoamines and their metabolites in Parkinson's disease

1 reference

12 December 2020

Cardiovascular effects of levodopa

1 reference

12 December 2020

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects

1 reference

12 December 2020

Monoamine oxidase inhibitors and L-dopa

1 reference

12 December 2020

The distribution of acetylcholine in the peripheral and the central nervous system

1 reference

12 December 2020

Caudate unit responses to nigral stimuli: evidence for a possible nigro-neostriatal pathway.

1 reference

12 December 2020

Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats

1 reference

12 December 2020

A REVIEW OF DRUG THERAPY IN PARKINSONISM

1 reference

12 December 2020

Levodopa in Parkinsonism: the Effects of Withdrawal of Anticholinergic Drugs

1 reference

12 December 2020

1 reference

12 December 2020

Effect of adrenergic beta-blockade on parkinsonian tremor

1 reference

12 December 2020

Identifiers

PubMed ID

4405376

1 reference

PubMed ID

4405376